UBS Group AG increased its stake in shares of Mazor Robotics Ltd. (NASDAQ:MZOR) by 2.4% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 99,954 shares of the medical instruments supplier’s stock after buying an additional 2,379 shares during the period. UBS Group AG owned about 0.42% of Mazor Robotics worth $2,976,000 at the end of the most recent quarter.
Several other institutional investors also recently modified their holdings of MZOR. JPMorgan Chase & Co. boosted its position in Mazor Robotics by 398.5% in the first quarter. JPMorgan Chase & Co. now owns 6,979 shares of the medical instruments supplier’s stock worth $208,000 after buying an additional 5,579 shares during the last quarter. Eagle Asset Management Inc. acquired a new position in Mazor Robotics during the first quarter worth $225,000. Menta Capital LLC acquired a new position in Mazor Robotics during the first quarter worth $815,000. Messner & Smith Theme Value Investment Management Ltd. CA acquired a new position in Mazor Robotics during the first quarter worth $872,000. Finally, Wells Fargo & Company MN boosted its position in Mazor Robotics by 46.3% in the first quarter. Wells Fargo & Company MN now owns 40,958 shares of the medical instruments supplier’s stock worth $1,220,000 after buying an additional 12,959 shares during the last quarter. 27.81% of the stock is owned by institutional investors and hedge funds.
Mazor Robotics Ltd. (NASDAQ:MZOR) traded up 0.55% during midday trading on Friday, hitting $39.88. The stock had a trading volume of 112,081 shares. The stock has a 50-day moving average price of $37.05 and a 200 day moving average price of $31.34. The firm’s market cap is $952.14 million. Mazor Robotics Ltd. has a 12-month low of $20.19 and a 12-month high of $45.64.
Mazor Robotics (NASDAQ:MZOR) last released its earnings results on Wednesday, May 10th. The medical instruments supplier reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.20) by $0.02. Mazor Robotics had a negative net margin of 45.08% and a negative return on equity of 30.90%. The business had revenue of $11.70 million for the quarter, compared to analyst estimates of $11.49 million. During the same period in the prior year, the company earned ($0.10) earnings per share. The firm’s revenue for the quarter was up 82.8% on a year-over-year basis. On average, equities analysts anticipate that Mazor Robotics Ltd. will post ($0.87) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This article was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.chaffeybreeze.com/2017/07/30/ubs-group-ag-buys-2379-shares-of-mazor-robotics-ltd-mzor-updated-updated-updated.html.
A number of equities analysts recently weighed in on the company. Zacks Investment Research cut Mazor Robotics from a “hold” rating to a “sell” rating in a report on Tuesday, July 18th. Needham & Company LLC reiterated a “hold” rating on shares of Mazor Robotics in a research note on Thursday, July 6th. Ladenburg Thalmann Financial Services reiterated a “buy” rating and set a $46.00 price objective on shares of Mazor Robotics in a research note on Monday, June 12th. ValuEngine upgraded Mazor Robotics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, B. Riley reiterated a “neutral” rating and set a $31.00 price objective on shares of Mazor Robotics in a research note on Monday, May 15th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and one has issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $33.50.
Mazor Robotics Company Profile
Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.
Receive News & Ratings for Mazor Robotics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.